Technical Analysis for FLXN - Flexion Therapeutics, Inc.

Grade Last Price % Change Price Change
F 11.14 0.54% 0.06
FLXN closed down 2.89 percent on Tuesday, March 2, 2021, on 74 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical FLXN trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.54%
Inside Day Range Contraction 0.54%
Oversold Stochastic Weakness 0.54%
Stochastic Buy Signal Bullish -2.37%
Oversold Stochastic Weakness -2.37%
NR7 Range Contraction 1.09%
Down 3 Days in a Row Weakness 1.09%
Oversold Stochastic Weakness 1.09%
Stochastic Reached Oversold Weakness 0.54%
Oversold Stochastic Weakness 0.54%
Older End-of-Day Signals for FLXN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Resistance 20 minutes ago
Up 1% 31 minutes ago
Fell Below Previous Day's Low 31 minutes ago
10 DMA Support about 24 hours ago
1.5x Volume Pace about 24 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Flexion Therapeutics, Inc. focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. Its lead product candidate includes FX006, an intra-articular, sustained-release triamcinolone acetonide, which has completed a Phase 2b dose-ranging clinical trial to treat moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a preclinical, small-molecule TrkA receptor antagonist to address post-operative pain; and FX005, an intra-articular, sustained-release p38 MAP kinase inhibitor, which has completed a Phase 2a clinical trial to treat end-stage OA patients. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pain Organic Compounds Burlington Osteoarthritis Organic Chemistry Arthritis Glucocorticoids Skeletal Disorders Organofluorides

Is FLXN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 15.58
52 Week Low 5.01
Average Volume 558,328
200-Day Moving Average 11.90
50-Day Moving Average 11.93
20-Day Moving Average 11.78
10-Day Moving Average 11.24
Average True Range 0.61
ADX 17.58
+DI 13.55
-DI 17.04
Chandelier Exit (Long, 3 ATRs ) 11.38
Chandelier Exit (Short, 3 ATRs ) 12.59
Upper Bollinger Band 13.17
Lower Bollinger Band 10.38
Percent B (%b) 0.25
BandWidth 23.70
MACD Line -0.27
MACD Signal Line -0.21
MACD Histogram -0.0632
Fundamentals Value
Market Cap 546.41 Million
Num Shares 49.3 Million
EPS -4.28
Price-to-Earnings (P/E) Ratio -2.59
Price-to-Sales 5.77
Price-to-Book 35.62
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.64
Resistance 3 (R3) 11.70 11.57 11.54
Resistance 2 (R2) 11.57 11.43 11.54 11.51
Resistance 1 (R1) 11.33 11.34 11.27 11.27 11.48
Pivot Point 11.20 11.20 11.17 11.17 11.20
Support 1 (S1) 10.96 11.06 10.90 10.90 10.68
Support 2 (S2) 10.83 10.97 10.80 10.65
Support 3 (S3) 10.59 10.83 10.62
Support 4 (S4) 10.53